A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).

• Biological: PF-06410293
  
  PF-06410293 will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
  Other Name: Adalimumab-Pfizer
• Biological: Adalimumab
  
  Adalimumab will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
  Other Name: Adalimumab-European Union, Humira

• Experimental: PF-06410293
  
  Intervention: Biological: PF-06410293
• Active Comparator: Adalimumab
  
  Intervention: Biological: Adalimumab

Inclusion Criteria:

• Diagnosis of rheumatoid arthritis based on 2010 ACR/EULAR criteria for at least 4 months.
• At least 6 tender (of 68 assessed) and 6 swollen (of 66 assessed) joints at screening and baseline.
• Hs-CRP equal or greater than 8 mg/L.
• Must have received methotrexate for at least 12 weeks and been on a stable dose for at least 4 weeks prior to the first study dose.

Exclusion Criteria:

• Evidence of untreated or inadequately treated latent or active TB.
• Evidence of uncontrolled, clinically significant diseases, including moderate or severe heart failure (NYHA Class III/IV) or malignancy in the previous 5 years.
• History of infection requiring hospitalization or parenteral antimicrobial therapy within 6 months prior to first dose of study drug.
• May have received no more than 2 doses of one biologic therapy (other than adalimumab or lymphocyte depleting therapy).
• Any second DMARD must be washed out prior to the first study dose.